Sarepta Therapeutics Cash Flow - Annual (NASDAQ:SRPT)

Add to My Stocks
$36.26 $1.54 (4.44%) SRPT stock closing price Apr 28, 2017 (Closing)

The financial analysis of SRPT requires an investor to check the cash flows for Sarepta Therapeutics. The profit-loss statement shows Sarepta Therapeutics profits, the balance sheet shows Sarepta Therapeutics debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. The cash flow statement is essetial while conducting the Sarepta Therapeutics cash flow analysis and can be used to measure the operating performance of Sarepta Therapeutics compared to various industry peers like BPMC stock and HALO stock. SRPT decrease in investments stood at a negative value of $-90.19M for the latest 2016. View details of Sarepta Therapeutics cash flows for latest & last ten financial years.

show more
Annual
Quarterly
View Previous Years
View Next Years
Fiscal year is Jan - Dec. 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Sarepta Therapeutics Net Income Cash Flow
-267.26M-220.03M-135.78M-111.98M-121.28M-2.31M-32.17M-25.15M-23.95M-27.16M
Depreciation Depletion Amortization Cash-Flow5.69M5.89M6.12M1.27M1.52M1.3M1.46M1.37M1.46M2.01M
Net Increase (Decrease) in Assets Liabilities-15.76M31.98M-22.13M12.26M-5.3M6.93M-0.35M2.93M-2.82M-0.35M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net31.52M32.68M23.26M33.74M95.37M-29.59M15.85M12.04M12.96M0.83M
Sarepta Therapeutics Net Cash from (used by) Operating Activities
-245.82M-149.46M-128.53M-64.69M-29.69M-23.67M-15.2M-8.8M-12.33M-24.67M
Increase (Decrease) in Prop Plant And Equipment-5.34M-3.4M-25.44M-2.37M-0.1M-1.17M-0.83M-0.93M-0.36M-1.27M
Acquisition Disposition of Subsidiaires---------0.01M-
Increase (Decrease) in Investments-83.32M13.24M-132.2M-7.89M---0.01M0.11M-0.01M12.7M
Other Cash Inflow (Outflow) from Investment Activities-1.52M-1.43M-1.38M-1.4M-1.03M-1.12M-1.12M-1.06M-0.84M-0.85M
Sarepta Therapeutics Net Cash from (used by) Invesment Activities
-90.19M8.41M-159.03M-11.67M-1.14M-2.3M-1.96M-1.88M-1.23M10.57M
Issuance (Purchase) of Equity Shares385.73M130.8M104.24M145.98M178.68M32.38M2.56M47.84M0.08M18.74M
Issuance (Repayment) of Debt Securities-7.6M17M-0.09M-0.08M-0.08M-0.08M-0.07M-0.07M-0.11M-
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities
Sarepta Therapeutics Net Cash from (used by) Financing Activities
378.12M147.8M104.15M145.67M178.59M32.29M2.48M47.76M-0.03M18.74M
Effect of Exchange Rate Changes on Cash----------
Sarepta Therapeutics Net Change in Cash & Cash Equivalents
42.11M6.75M-183.41M69.3M147.75M6.31M-14.68M37.08M-13.61M4.64M
Cash & Equivalents at Beginning of Year80.3M73.55M256.96M187.66M39.9M33.58M48.27M11.19M24.8M20.15M
Cash & Equivalents at Year End122.42M80.3M73.55M256.96M187.66M39.9M33.58M48.27M11.19M24.8M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years
Get Cash flow for another ticker

1:11
SRPT
While Sarepta Therapeutics stock price history provides the price history of a stock, Sarepta Therapeutics stock comparison chart shows the same in comparison to peers, and cash flow statements provide cash position of the company. Common terms used in the statement of cash flows are:
  • Sarepta Therapeutics has cash of $122.42M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Sarepta Therapeutics stock price.
  • Cash Flow from operating activities: Sarepta Therapeutics reported a negative operating cash flow of $-245.82M for 2016 and has seen a decrease from the previous year. Operating cash flow or working capital comes from main business activities. Investors look for positive cash flow from recurring operating activities.
  • Growth companies (typically most tech companies) spend heavily  on investing activities and this figure was negative at $-90.19M for SRPT stock. Sometimes a company might have a negative overall cash flow which may not be really bad if it is due to investment expenses. Hence it is important to check the cash flow from investment activities.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $378.12M for Sarepta Therapeutics. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.
.

Key Financial Ratios For Sarepta Therapeutics Cash Flow

FCF margin
-3.88